drugset / Trial / NCT00237380
Safety and Efficacy of Ataluren (PTC124) for Cystic Fibrosis
NaSingle-groupOpen-labelTreatment
Summary
In some participants with cystic fibrosis (CF), the disease is caused by a nonsense mutation (premature stop codon) in the gene that makes the cystic fibrosis transmembrane regulator (CFTR) protein. Ataluren has been shown to partially restore CFTR production in animals with CF due to a nonsense mutation. The main purpose of this study is to understand whether ataluren can safely increase functional CFTR protein in the cells of participants with CF due to a nonsense mutation.
Timeline
- Start
- 2005-11-30
- Primary completion
- 2006-05-31
- Completion
- 2006-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ataluren | Small molecule | 16 mg/kg | Oral |
| Subject | Ataluren | Small molecule | 40 mg/kg | Oral |